PT  - JOURNAL ARTICLE
AU  - George A. Margaritopoulos
AU  - Katerina M. Antoniou
AU  - Athol U. Wells
TI  - Comorbidities in interstitial lung diseases
AID  - 10.1183/16000617.0027-2016
DP  - 2017 Mar 31
TA  - European Respiratory Review
PG  - 160027
VI  - 26
IP  - 143
4099  - http://err.ersjournals.com/content/26/143/160027.short
4100  - http://err.ersjournals.com/content/26/143/160027.full
SO  - EUROPEAN RESPIRATORY REVIEW2017 Mar 31; 26
AB  - Fibrosing lung disorders include a large number of diseases with diverse behaviour. Patients can die because of the progression of their illness, remain stable or even improve after appropriate treatment has been instituted. Comorbidities, such as acute and chronic infection, gastro-oesophageal reflux, pulmonary hypertension, lung cancer, cardiovascular diseases, and obstructive sleep apnoea, can pre-exist or develop at any time during the course of the disease and, if unidentified and untreated, may impair quality of life, impact upon the respiratory status of the patients, and ultimately lead to disease progression and death. Therefore, early identification and accurate treatment of comorbidities is essential.Early detection and accurate management of comorbidity have benefits in reducing ILD morbidity and mortality http://ow.ly/4nmYie